Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Adaptive Biotechnologies CorpADPT · Entity 1126 | President and COO | October 09, 2026 | October 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Adaptive Biotechnologies Corp
Report date October 09, 2026 · Filed October 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 377,802 |
Ending reported balance
After 2026-10-13 transaction · row 7
7 source rows · reconciled sequenceRow 1 · 2026-10-09 · Exercise / conversion · Acquired 11,881 · Balance 389,683 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. Row 2 · 2026-10-09 · Sale · Disposed 11,881 · Balance 377,802 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F2: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.99 to $26.80, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Row 3 · 2026-10-12 · Exercise / conversion · Acquired 11,881 · Balance 389,683 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. Row 4 · 2026-10-12 · Sale · Disposed 9,181 · Balance 380,502 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F3: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.82 to $25.81, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Row 5 · 2026-10-12 · Sale · Disposed 2,700 · Balance 377,802 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F4: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.83 to $26.31, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Row 6 · 2026-10-13 · Exercise / conversion · Acquired 11,881 · Balance 389,683 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. Row 7 · 2026-10-13 · Sale · Disposed 11,881 · Balance 377,802 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F5: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.10 to $25.80, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.14 · Expires 2032-03-04 | Direct | 296,610 |
Reported balance
After 2026-10-09 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-10-09 · Exercise / conversion · Disposed 11,881 · Balance 296,610 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F6: The option is fully vested and exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.14 · Expires 2032-03-04 | Direct | 284,729 |
Reported balance
After 2026-10-12 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-10-12 · Exercise / conversion · Disposed 11,881 · Balance 284,729 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F6: The option is fully vested and exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.14 · Expires 2032-03-04 | Direct | 272,848 |
Reported balance
After 2026-10-13 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-10-13 · Exercise / conversion · Disposed 11,881 · Balance 272,848 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F6: The option is fully vested and exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.
F2: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.99 to $26.80, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F3: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.82 to $25.81, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F4: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.83 to $26.31, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F5: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.10 to $25.80, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F6: The option is fully vested and exercisable.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 13, 2026 Filed Oct 13, 2026 23:05 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (right to buy) · Derivative | 11,881 | $0.00 Strike: $12.14 | $0.00 |
DisclosureSEC source: 0001780664-26-000039 · form4.xml · derivative · entry 10 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 272,848 Underlying: Common Stock · 11,881 shares Expires 2032-03-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F6 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| October 13, 2026 Filed Oct 13, 2026 23:05 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 11,881 | $25.50 | $302,965.50 |
DisclosureSEC source: 0001780664-26-000039 · form4.xml · nonDerivative · entry 7 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 377,802 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F5 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.10 to $25.80, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| October 13, 2026 Filed Oct 13, 2026 23:05 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 11,881 | $12.14 | $144,235.34 |
DisclosureSEC source: 0001780664-26-000039 · form4.xml · nonDerivative · entry 6 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 389,683 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. Read SEC document |
| October 12, 2026 Filed Oct 13, 2026 23:05 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (right to buy) · Derivative | 11,881 | $0.00 Strike: $12.14 | $0.00 |
DisclosureSEC source: 0001780664-26-000039 · form4.xml · derivative · entry 9 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 284,729 Underlying: Common Stock · 11,881 shares Expires 2032-03-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F6 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| October 12, 2026 Filed Oct 13, 2026 23:05 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 2,700 | $26.07 | $70,389.00 |
DisclosureSEC source: 0001780664-26-000039 · form4.xml · nonDerivative · entry 5 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 377,802 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F4 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.83 to $26.31, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| October 12, 2026 Filed Oct 13, 2026 23:05 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 9,181 | $25.35 | $232,738.35 |
DisclosureSEC source: 0001780664-26-000039 · form4.xml · nonDerivative · entry 4 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 380,502 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F3 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.82 to $25.81, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| October 12, 2026 Filed Oct 13, 2026 23:05 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 11,881 | $12.14 | $144,235.34 |
DisclosureSEC source: 0001780664-26-000039 · form4.xml · nonDerivative · entry 3 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 389,683 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. Read SEC document |
| October 09, 2026 Filed Oct 13, 2026 23:05 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (right to buy) · Derivative | 11,881 | $0.00 Strike: $12.14 | $0.00 |
DisclosureSEC source: 0001780664-26-000039 · form4.xml · derivative · entry 8 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 296,610 Underlying: Common Stock · 11,881 shares Expires 2032-03-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F6 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| October 09, 2026 Filed Oct 13, 2026 23:05 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 11,881 | $26.41 | $313,777.21 |
DisclosureSEC source: 0001780664-26-000039 · form4.xml · nonDerivative · entry 2 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 377,802 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F2 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.99 to $26.80, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| October 09, 2026 Filed Oct 13, 2026 23:05 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 11,881 | $12.14 | $144,235.34 |
DisclosureSEC source: 0001780664-26-000039 · form4.xml · nonDerivative · entry 1 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 389,683 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. Read SEC document |
| October 08, 2026 Filed Oct 8, 2026 22:54 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (right to buy) · Derivative | 11,881 | $0.00 Strike: $12.14 | $0.00 |
DisclosureSEC source: 0001780664-26-000037 · form4.xml · derivative · entry 12 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 308,491 Underlying: Common Stock · 11,881 shares Expires 2032-03-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F8 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| October 08, 2026 Filed Oct 8, 2026 22:54 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 11,881 | $25.66 | $304,866.46 |
DisclosureSEC source: 0001780664-26-000037 · form4.xml · nonDerivative · entry 9 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 377,802 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F7 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.23 to $26.09, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| October 08, 2026 Filed Oct 8, 2026 22:54 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 11,881 | $12.14 | $144,235.34 |
DisclosureSEC source: 0001780664-26-000037 · form4.xml · nonDerivative · entry 8 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 389,683 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. Read SEC document |
| October 07, 2026 Filed Oct 8, 2026 22:54 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (right to buy) · Derivative | 11,881 | $0.00 Strike: $12.14 | $0.00 |
DisclosureSEC source: 0001780664-26-000037 · form4.xml · derivative · entry 11 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 320,372 Underlying: Common Stock · 11,881 shares Expires 2032-03-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F8 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| October 07, 2026 Filed Oct 8, 2026 22:54 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 11,881 | $26.40 | $313,658.40 |
DisclosureSEC source: 0001780664-26-000037 · form4.xml · nonDerivative · entry 7 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 377,802 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F6 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.95 to $26.88, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| October 07, 2026 Filed Oct 8, 2026 22:54 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 11,881 | $12.14 | $144,235.34 |
DisclosureSEC source: 0001780664-26-000037 · form4.xml · nonDerivative · entry 6 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 389,683 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. Read SEC document |
| October 06, 2026 Filed Oct 8, 2026 22:54 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (right to buy) · Derivative | 11,881 | $0.00 Strike: $12.14 | $0.00 |
DisclosureSEC source: 0001780664-26-000037 · form4.xml · derivative · entry 10 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 332,253 Underlying: Common Stock · 11,881 shares Expires 2032-03-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F8 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| October 06, 2026 Filed Oct 8, 2026 22:54 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 499 | $30.53 | $15,234.47 |
DisclosureSEC source: 0001780664-26-000037 · form4.xml · nonDerivative · entry 5 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 377,802 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F5 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.34 to $30.68, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| October 06, 2026 Filed Oct 8, 2026 22:54 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 901 | $29.71 | $26,768.71 |
DisclosureSEC source: 0001780664-26-000037 · form4.xml · nonDerivative · entry 4 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 378,301 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F4 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.19 to $30.18, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| October 06, 2026 Filed Oct 8, 2026 22:54 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 1,100 | $28.21 | $31,031.00 |
DisclosureSEC source: 0001780664-26-000037 · form4.xml · nonDerivative · entry 3 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 379,202 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F3 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.89 to $28.75, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| October 06, 2026 Filed Oct 8, 2026 22:54 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 9,381 | $27.36 | $256,664.16 |
DisclosureSEC source: 0001780664-26-000037 · form4.xml · nonDerivative · entry 2 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 380,302 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F2 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.89 to $27.87, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| October 06, 2026 Filed Oct 8, 2026 22:54 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 11,881 | $12.14 | $144,235.34 |
DisclosureSEC source: 0001780664-26-000037 · form4.xml · nonDerivative · entry 1 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 389,683 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. Read SEC document |
| October 05, 2026 Filed Oct 6, 2026 00:15 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (right to buy) · Derivative | 11,881 | $0.00 Strike: $12.14 | $0.00 |
DisclosureSEC source: 0001780664-26-000035 · form4.xml · derivative · entry 11 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 344,134 Underlying: Common Stock · 11,881 shares Expires 2032-03-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F7 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| October 05, 2026 Filed Oct 6, 2026 00:15 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 5,182 | $29.67 | $153,749.94 |
DisclosureSEC source: 0001780664-26-000035 · form4.xml · nonDerivative · entry 8 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 377,802 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F6 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.32 to $29.82, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| October 05, 2026 Filed Oct 6, 2026 00:15 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 6,699 | $28.82 | $193,065.18 |
DisclosureSEC source: 0001780664-26-000035 · form4.xml · nonDerivative · entry 7 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 382,984 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F5 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.30 to $29.29, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| October 05, 2026 Filed Oct 6, 2026 00:15 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 11,881 | $12.14 | $144,235.34 |
DisclosureSEC source: 0001780664-26-000035 · form4.xml · nonDerivative · entry 6 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 389,683 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. Read SEC document |
| October 02, 2026 Filed Oct 6, 2026 00:15 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (right to buy) · Derivative | 11,881 | $0.00 Strike: $12.14 | $0.00 |
DisclosureSEC source: 0001780664-26-000035 · form4.xml · derivative · entry 10 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 356,015 Underlying: Common Stock · 11,881 shares Expires 2032-03-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F7 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| October 02, 2026 Filed Oct 6, 2026 00:15 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 11,881 | $28.13 | $334,212.53 |
DisclosureSEC source: 0001780664-26-000035 · form4.xml · nonDerivative · entry 5 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 377,802 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F4 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.62 to $28.37, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| October 02, 2026 Filed Oct 6, 2026 00:15 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 11,881 | $12.14 | $144,235.34 |
DisclosureSEC source: 0001780664-26-000035 · form4.xml · nonDerivative · entry 4 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 389,683 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. Read SEC document |
| October 01, 2026 Filed Oct 6, 2026 00:15 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (right to buy) · Derivative | 11,881 | $0.00 Strike: $12.14 | $0.00 |
DisclosureSEC source: 0001780664-26-000035 · form4.xml · derivative · entry 9 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 367,896 Underlying: Common Stock · 11,881 shares Expires 2032-03-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F7 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| October 01, 2026 Filed Oct 6, 2026 00:15 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 5,800 | $28.56 | $165,648.00 |
DisclosureSEC source: 0001780664-26-000035 · form4.xml · nonDerivative · entry 3 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 377,802 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F3 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.22 to $28.83, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| October 01, 2026 Filed Oct 6, 2026 00:15 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 6,081 | $27.57 | $167,653.17 |
DisclosureSEC source: 0001780664-26-000035 · form4.xml · nonDerivative · entry 2 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 383,602 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F2 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.22 to $28.11, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| October 01, 2026 Filed Oct 6, 2026 00:15 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 11,881 | $12.14 | $144,235.34 |
DisclosureSEC source: 0001780664-26-000035 · form4.xml · nonDerivative · entry 1 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 389,683 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. Read SEC document |
| April 27, 2026 Filed Apr 29, 2026 23:08 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (right to buy) · Derivative | 14,707 | $0.00 Strike: $8.46 | $0.00 |
DisclosureSEC source: 0001780664-26-000032 · form4.xml · derivative · entry 3 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 45,731 Underlying: Common Stock · 14,707 shares Expires 2033-03-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F3 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on March 4, 2024, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| April 27, 2026 Filed Apr 29, 2026 23:08 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 19,037 | $14.23 | $270,896.51 |
DisclosureSEC source: 0001780664-26-000032 · form4.xml · nonDerivative · entry 2 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 377,802 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F2 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.08 to $14.34, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| April 27, 2026 Filed Apr 29, 2026 23:08 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 14,707 | $8.46 | $124,421.22 |
DisclosureSEC source: 0001780664-26-000032 · form4.xml · nonDerivative · entry 1 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 396,839 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. Read SEC document |
| April 24, 2026 Filed Apr 24, 2026 22:29 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (right to buy) · Derivative | 14,722 | $0.00 Strike: $8.46 | $0.00 |
DisclosureSEC source: 0001780664-26-000030 · form4.xml · derivative · entry 9 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 60,438 Underlying: Common Stock · 14,722 shares Expires 2033-03-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F5 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on March 4, 2024, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| April 24, 2026 Filed Apr 24, 2026 22:29 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 19,060 | $14.02 | $267,221.20 |
DisclosureSEC source: 0001780664-26-000030 · form4.xml · nonDerivative · entry 6 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 382,132 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F4 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.79 to $14.16, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| April 24, 2026 Filed Apr 24, 2026 22:29 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 14,722 | $8.46 | $124,548.12 |
DisclosureSEC source: 0001780664-26-000030 · form4.xml · nonDerivative · entry 5 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 401,192 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. Read SEC document |
| April 23, 2026 Filed Apr 24, 2026 22:29 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (right to buy) · Derivative | 14,722 | $0.00 Strike: $8.46 | $0.00 |
DisclosureSEC source: 0001780664-26-000030 · form4.xml · derivative · entry 8 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 75,160 Underlying: Common Stock · 14,722 shares Expires 2033-03-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F5 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on March 4, 2024, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| April 23, 2026 Filed Apr 24, 2026 22:29 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 19,060 | $13.74 | $261,884.40 |
DisclosureSEC source: 0001780664-26-000030 · form4.xml · nonDerivative · entry 4 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 386,470 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F3 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.52 to $14.14, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| April 23, 2026 Filed Apr 24, 2026 22:29 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 14,722 | $8.46 | $124,548.12 |
DisclosureSEC source: 0001780664-26-000030 · form4.xml · nonDerivative · entry 3 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 405,530 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. Read SEC document |
| April 22, 2026 Filed Apr 24, 2026 22:29 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (right to buy) · Derivative | 14,722 | $0.00 Strike: $8.46 | $0.00 |
DisclosureSEC source: 0001780664-26-000030 · form4.xml · derivative · entry 7 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 89,882 Underlying: Common Stock · 14,722 shares Expires 2033-03-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F5 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on March 4, 2024, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| April 22, 2026 Filed Apr 24, 2026 22:29 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 19,060 | $14.13 | $269,317.80 |
DisclosureSEC source: 0001780664-26-000030 · form4.xml · nonDerivative · entry 2 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 390,808 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F2 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.97 to $14.44, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| April 22, 2026 Filed Apr 24, 2026 22:29 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 14,722 | $8.46 | $124,548.12 |
DisclosureSEC source: 0001780664-26-000030 · form4.xml · nonDerivative · entry 1 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 409,868 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. Read SEC document |
| April 21, 2026 Filed Apr 21, 2026 22:07 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (right to buy) · Derivative | 11,881 | $0.00 Strike: $12.14 | $0.00 |
DisclosureSEC source: 0001780664-26-000028 · form4.xml · derivative · entry 11 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 379,777 Underlying: Common Stock · 11,881 shares Expires 2032-03-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F6 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| April 21, 2026 Filed Apr 21, 2026 22:07 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (right to buy) · Derivative | 14,722 | $0.00 Strike: $8.46 | $0.00 |
DisclosureSEC source: 0001780664-26-000028 · form4.xml · derivative · entry 10 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 104,604 Underlying: Common Stock · 14,722 shares Expires 2033-03-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F5 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on March 4, 2024, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| April 21, 2026 Filed Apr 21, 2026 22:07 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 30,941 | $14.66 | $453,595.06 |
DisclosureSEC source: 0001780664-26-000028 · form4.xml · nonDerivative · entry 7 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 395,146 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F4 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.18 to $15.13, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| April 21, 2026 Filed Apr 21, 2026 22:07 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 11,881 | $12.14 | $144,235.34 |
DisclosureSEC source: 0001780664-26-000028 · form4.xml · nonDerivative · entry 6 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 426,087 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. Read SEC document |
| April 21, 2026 Filed Apr 21, 2026 22:07 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 14,722 | $8.46 | $124,548.12 |
DisclosureSEC source: 0001780664-26-000028 · form4.xml · nonDerivative · entry 5 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 414,206 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.